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Metallothioneins (MTs) are a group of ubiquitous low molecular
mass, cysteine-rich intracellular metal-binding proteins (Kagi and
Schaffer, 1988). MTs are known to play putative roles in cancer
cell proliferation and apoptosis (Abdel-Mageed and Agrawal,
1997; Jayasurya et al, 2000) as well as in resistance to radiation
and chemotherapeutic agents (Lohrer and Robson, 1989; Yang et
al, 1994, Kondo et al, 1995). In breast cancer, MT overexpression
has been well documented by immunohistochemical analysis
(Schmid et al, 1993; Fresno et al, 1993; Haerslev et al, 1995;
Goulding et al, 1995; Jin et al, 1999), and shown to be predomi-
nantly associated with poor prognosis.
In humans, the MTs are encoded by a family of genes consisting
of 10 functional MT isoforms and the encoded proteins are
conventionally subdivided into four groups viz, MT-1, MT-2, MT-
3 and MT-4 proteins (Palmiter et al, 1992; Stennard et al, 1994;
Quaife et al, 1994; Mididoddi et al, 1996). While a single MT-2A
gene encodes MT-2 protein, MT-1 protein comprises many
subtypes encoded by a set of MT-1 genes (MT-1A, MT 1-B, MT-
1E, MT-1F, MT-1G, MT-1H and MT-1X) accounting for the
microheterogeneity of the MT-1 protein (Karin et al, 1984).
Different MT genes in humans possibly play different functional
roles during development or under various physiological condi-
tions (Kagi and Schaffer, 1988).
Differential expression of the MT-1E gene in oestrogen receptor
(OR)-positive and -negative human breast cancer cell lines has
been recently reported (Friedline et al, 1998). In that study, two
OR-positive breast cancer cell lines (MCF7 and T-47D) showed no
detectable MT-1E gene expression, whereas two OR-negative cell
lines (MDA-MB-231 and Hs578T) expressed high levels of MT-
1E mRNA. However, to the best of our knowledge, there is
hitherto no available data on MT-1E mRNA expression in clinical
breast cancer tissues, as most of published reports are on cell lines.
In light of the above findings, the aims of this study were to: a)
analyse MT-1E mRNA expression in human invasive ductal breast
cancer tissues concurrently with MCF7 and MDA-MB-231 human
breast cancer cells; b) evaluate the association between MT-1E
mRNA expression and the OR status of breast cancer tissues and;
c) explore the relationship between MT-1E mRNA expression and
PR status using PR-transfected MDA-MB-231 cell lines and
breast cancer tissues.
MATERIALS AND METHODS
Human breast cancer tissues
Fifty-one primary invasive ductal breast cancer tissues were
randomly obtained from mastectomies at the Singapore General
Hospital (SGH). The diagnoses of invasive ductal breast cancer
were made according to standard criteria defined by the World
Health Organization (Elston and Ellis, 1998). None of the cases
received chemotherapy or radiotherapy before surgery. The tissue
samples were harvested by pathologists who divided each sample
into two parts. One part was fixed in 10% formalin and embedded
in paraffin for routine diagnosis by haematoxylin and eosin
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status. The other part, which was determined macroscopically as
comprising only tumour tissue, was snap-frozen and stored in
liquid nitrogen for mRNA analysis.
Cell culture
All cells were routinely maintained in phenol-red containing
Dulbecco’s modified Eagle medium (DMEM) supplemented with
5% foetal calf serum (FCS), 2 mM glutamine and 40 mg l–1
gentamicin. For all experiments, cells were grown in phenol-red-
free DMEM supplemented with 5% dextran charcoal-treated fetal
calf serum (DCC-FCS) to remove endogenous steroid hormones
that might interfere with the analysis. Cells were treated with prog-
esterone from a 1000-fold stock in ethanol, giving a final ethanol
concentration of 0.1%. Treatment controls received 0.1% ethanol
only. MCF-7 (OR+, PR+) and MDA-MB-231 (OR–, PR–) cells
were obtained from the American Type Culture Collection.
Transfection
Transfection of PR cDNA into OR- and PR-negative MDA-MB-
231 breast cancer cells is as described previously (Lin et al, 1999).
PR expression vectors hPR1 and hPR2 were generous gifts from
Professor Chambon P (IGBMC, France). Vectors hPR1 and hPR2
contained human PR cDNA encoding PR isoform B and isoform
A, respectively, in pSG5 plasmid. Vector pBK-CMV (Stratagene,
La Jolla, USA) containing the neomycin-resistant gene was co-
transfected with hPR1 and hPR2 into MDA-MB-231-CL2 cells.
Neomycin-resistant clones were screened for PR using the PR
enzyme immunoassay (EIA) kit (Abbott Laboratories, Illinois,
USA). Eight PR-positive clones expressing both isoforms A and B
were isolated and characterized. They showed similar responses to
progesterone treatment (Lin et al, 1999). The effects of proges-
terone on MT-1E mRNA expression in clone ABC28 that
expressed ~660 fmol PR per mg protein were studied in this
report. Cells stably transfected with both vectors pBK-CMV and
pSG5 (clone pSG5-c15) served as control transfectant.
RT-PCR analysis
Total RNA was isolated using the RNeasy Mini kit (QIAGEN,
Hilden, Germany) according to the manufacturer’s protocol. The
concentration and purity of the extracted RNA were evaluated by
spectrophotometric absorbance readings at 260 and 280 nm.
Total RNA was reverse-transcribed using Superscript II RNase
H– reverse transcriptase (Life Technologies, Gaithersburg, USA)
in 1 ´ RT buffer (50 mM Tris-HCl pH 8.3, 75 mM KCl, 3 mM
MgCl2), 0.01 M DTT, 0.5 U ml–1 RNase inhibitor, 0.33 mM of 
each dNTP, and 0.003 OD260 U ml–1 random primers (Life
Technologies). The samples were incubated at room temperature
for 10 min, then at 42°C for 60 min, followed by 5 min at 99°C,
and at 4°C for 5 min. Each cDNA sample equivalent to about 80
ng total RNA was then used for PCR amplification. Twenty-five
PCR cycles were used, each consisting of denaturation for 30 s at
95°C, annealing for 30 s at 65°C, and extension for 30 s at 72°C.
The initial step was 95°C for 1 min, with a final elongation step of
72°C for 7 min. The PCR primers used were as described by
Mididoddi et al (1996). The resultant PCR products were elec-
trophoresed in 1.6% agarose gels containing ethidium bromide
along with DNA markers, visualized under UV, and analysed by
densitometric scanning (Bio-Rad model GS-700 Imaging
Densitometer) using the Molecular Analyst Software (Bio-Rad
Laboratories version 1.5). Two to three independent PCRs were
performed to control for variations between experiments. A no-
template control in which water was added instead of RNA and a
no-reverse transcriptase control in which water was added instead
of the enzyme were included for each PCR batch. For semi-quan-
titative analysis, mRNA of the housekeeping gene glyceralde-
hyde-3-phosphate dehydrogenase (G3PDH) was co-amplified
under the same conditions using the amplimers described by
Abdel-Mageed et al (1997). The relative expression level of each
MT isoform compared to G3PDH gene expression was deter-
mined. A prior PCR cycle optimization was conducted to ensure
that all the reactions remained in the linear region (by removal and
analysis of samples at 15, 20, 25, 30 and 35 cycles). A selected
pre-experimental RT-PCR product was proven to be actual MT-1E
isoforms by cycle dideoxy DNA sequencing, and several represen-
tative PCR products were reconfirmed by restriction endonuclease
digestion analysis.
Restriction endonuclease digestion of MT-1E RT-PCR
products
Following RT-PCR, 15 ml of PCR product was subjected to restric-
tion enzyme digestion by adding 2 ml of relevant buffer, 10 units
Bgl-I or Ear-I enzyme (New England BioLabs, Beverly, MA,
USA) with 3 ml distilled water to a final volume of 20 ml.
Following incubation at 37°C for 1 h, the reaction was terminated
by adding 5 ml gel-loading buffer, samples were electrophoresed in
1.6% agarose gels along with DNA markers and visualized under
UV. Based on the specific sequence in the 5¢ and 3¢ untranslated
regions of the active MT-1E gene (Mididoddi et al, 1996), the MT-
1E primers can amplify a 284-bp RT-PCR product with a Bgl-I site
that would give rise to two fragments (164 bp and 120 bp). Two
Ear-I sites within the target amplicon would be expected to result
in three fragments (137 bp, 108 bp and 39 bp), provided the reac-
tion was also specific for the MT-1E gene.
Immunohistochemistry
OR and PR status were respectively determined by immunohisto-
chemistry. 3 mm sections were cut from each block, mounted
on slides coated with ‘APES’ (3-aminopropyltriethoxysilane;
purchased from Sigma; St. Louis, MO, USA) and dried overnight
at 55°C. The sections were deparaffinized and rehydrated.
Endogenous peroxidase activity was blocked by dipping the slides
in 12 ml of methanol containing 200 ml hydrogen peroxide for 10
min followed by washing in tap water. The slides were then placed
in 0.01 M citrate buffer (pH 6.0) and pressure cooked for 2 min
before washing in tap water and rinsing with Tris buffered saline
(TBS) at pH 7.6. The primary antibody was then applied. The
oestrogen receptor primary antibody used was ERID5 clone (Dako
Copenhagen, Denmark), at 1:30 dilution. The progesterone
receptor primary antibody used was PRIA6 clone (Dako) at 1:30
dilution. The primary antibody was incubated for 1 h before rinsing
off with TBS. This was followed by incubation with biotinylated
anti-mouse immunoglobulin for 20 min, after which the sections
were incubated with streptavidin–biotin complex for another
20 min. Freshly prepared DAB (5 mg 3,3-diaminoazobenzidine
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pH 7.6 containing 100 ml of 1% hydrogen peroxide, was applied for
10 min after the tertiary layer was rinsed off with TBS. DAB was
removed by rinsing with TBS and the slides were counterstained
with haematoxylin. They were then differentiated in 0.5% acid
alcohol and placed under running water. The final steps were dehy-
dration, clearing and mounting in depex. Positive OR and PR
staining was defined when 10% or more of tumour cell nuclei were
immunoreactive.
Statistical analysis
The Graphpad Prism software package was used for statistical
analysis. Non-parametric Mann–Whitney test was performed to
compare sample medians. Pearson’s correlation was used to
analyse the relationship between MT-1E mRNA expression with
age and tumour size.
RESULTS
MT-1E mRNA expression and specificity
Except for one OR-positive breast cancer sample, the mRNA of
the MT-1E isoform was detected via RT-PCR in the other 50
cancerous samples (Figure 1). The mean ratio of MT-1E expres-
sion (relative to housekeeping gene G3PDH) was 0.52 ± 0.04
(± sem). The frequency histogram is shown in Figure 2. One OR-
negative breast cancer sample had a very high level of MT-1E
mRNA expression (ratio was 1.99). OR- and PR-positive MCF7
cells showed no detectable MT-1E mRNA expression, whereas
OR- and PR-negative MDA-MB-231 cells exhibited high levels of
MT-1E mRNA expression (Figure 3).
The specificity of the MT-1E RT-PCR products was confirmed
by sequencing and restriction enzyme digestion of representative
RT-PCR products. Restriction enzyme digestion of MT-1E RT-
PCR product is exemplified in Figure 4.
MT-1E mRNA expression and steroid receptor status
As evaluated by immunohistochemistry, 35 samples were OR-
positive and 16 cases were OR-negative, while 17 cases were PR-
positive with 34 PR-negative cases (Table 1).
High MT-1E mRNA expression in OR-negative tumour
compared with OR-positive tumours was statistically significant
(0.68 ± 0.10 vs 0.45 ± 0.04, P = 0.026). There was no significant
difference of MT-1E expression between PR-negative and PR-
positive breast tumours (0.54 ± 0.058 vs 0.46 ± 0.053, P = 0.43),
nor was there a significant difference between PR-positive and
PR-negative tumours in the OR-positive subgroup (0.46 ± 0.053 vs
0.44 ± 0.053, P = 0.79) (Table 1).
In order to confirm whether MT-1E expression is affected by PR
expression and progesterone treatment, we examined MT-1E
mRNA levels in PR-transfected MDA-MB-231 breast cancer cells
clone ABC28 and in untransfected controls. PR transfectant
ABC28 cells expressed similar levels of MT-1E mRNA as the OR-
and PR-negative control transfectant pSG5–C15 and the parental
cell line MDA-MB-231-C2 (Figure 3). Treatment of ABC28 cells
with 0.1 mM Progesterone for 24 h had no effect on MT-1E expres-
sion compared with vehicle-treated controls (Figure 3, lanes 6 and
7). To further validate the results, we tested the effect of proges-
terone treatment on MT-1E expression in ABC28 cells at a series
of time points (data not shown). Again, there was no difference in
MT-1E gene expression after 3, 6, 9 and 24 h of treatment between
progesterone-treated and vehicle-treated control ABC28 cells
which had been shown to respond to progesterone treatment in a
number of cellular processes such as cellular proliferation and
focal adhesion (Lin et al, 1999; 2000).
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Figure 1 Example of MT-IE mRNA expression (reflected by 284 bp RT-PCR
products) in invasive ductal carcinomas. Top panel: DNA markers (lanes 1
and 8), OR-positive cancer tissue from the same sample (lanes 2 and 3),
OR-negative cancer tissue (lanes 4 and 5), ‘no RNA’ control (lane 6) and ‘no-
reverse transcript’ control. Bottom panel: housekeeping gene G3PDH
expression (160 bp RT-PCR product) corresponding to lanes in top panel
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Figure 3 Agarose gel electrophoresis showing MT-1E mRNA expression in
breast cancer cell lines. DNA marker (lanes 1 and 14), MCF7 (lane 2), MDA-
MB-231 (lane 3), ABC28 cells (lane 4), pSG5-C15 cells (lane 5), ABC28 cells
under 24 h of progesterone treatment (lane 6) and 0.1% ethanol treatment
(lane 7). Lanes 8 to 13 show housekeeping gene G3PDH expression
corresponding to lanes 2–7, respectively.
Figure 2 Frequency histogram of MT-1E mRNA expression level (relative
to expression of G3PDH) in breast cancer tissuesNo significant associations were observed between MT-1E
mRNA expression and other clinicopathological factors, such as
patient age, tumour size and histological grade.
DISCUSSION
Physical mapping studies have shown that all known functional
human MT-1 and MT-2 genes are clustered on chromosome
16q13. MT isoforms display specific developmental expression
patterns (Andrews et al, 1991) as well as cell-type-specific and
inducer-specific regulation (Richards et al, 1984; Schmidt 
and Hamer, 1986; Jahroudi et al, 1990; Cavigelli et al, 1993). In
addition, MT primary sequences are highly conserved among
vertebrates. It is therefore not surprising that members of the MT
family may be involved pleiotropically in a number of different
biological functions (Kagi and Schaffer, 1988).
Since the coding regions of MT isoforms are highly conserved,
experiments on any individual isoform should be very carefully
conducted to ensure that the exact isoform is analysed. In this
study, we authenticated actual MT-1E gene amplification by gene
sequencing and restriction enzyme digestion analyses. Our results
showing no detectable MT-1E expression in OR-positive MCF 7
breast cancer cells and high levels of MT-1E expression in the OR-
negative breast cancer cell line MDA-MB-231 concurs with the
finding of Friedline and co-workers (1998). Furthermore, we
demonstrated significantly higher MT-1E mRNA expression
levels in OR-negative than in OR-positive human breast cancer
tissues. It is also interesting to note that one of the OR-negative
breast cancer samples, had an outstandingly high level of MT-1E
expression. This overexpression of MT-1E in this breast cancer
tissue could be explained by the possibility of a gene mutation, as
recently suggested by Jasani et al (1998).
Oestrogen receptor status is an important prognostic marker of
breast cancer. OR-negative tumours generally incur a poor prog-
nosis and are resistant to hormone therapy (Rich et al, 1978;
McKenzie and Sukumar, 1996). Oestrogen and progesterone play
central roles in normal breast development, as well as in breast
carcinogenesis, by regulating the expression of a variety of genes
through their receptors (Celentano et al, 1998). The oestrogen
receptor is considered to be a ligand-activated transcription factor
which upon oestrogen binding alters transcription of target genes,
thereby affecting cellular processes such as mitogenesis (Murphy
et al, 1998; Dowsett, 1998).
Transformation from an OR- and PR-positive hormone-depen-
dent tumour to an OR- and PR-negative hormone-independent
tumour is a crucial step in the progression of breast cancer. This
process would require an alternative mechanism to replace the
functions of oestrogen and progesterone (Mckenzie and Sukumar,
1996). It is possible that MT-1E may participate in that role. MTs
are known to influence tumour growth and survival by promoting
cell proliferation and cellular repair processes, enhancing resis-
tance to chemotherapy and inhibiting apoptosis (Kagi 1991;
Kondo et al, 1995; Abdel-Mageed and Agrawal, 1997; Jayasurya
et al, 2000). High MT expression has also been reported to be
associated with aggressive behaviour in endometrial carcinoma
(McCluggage et al, 1999). The known biological functions of MT
and the association of MT-1E with OR-breast cancer concurs with
the observation that breast cancer patients who do not exhibit ORs
have a poorer prognosis and decreased disease-free survival as
compared with patients whose tumours contained ORs (Wittliff et
al, 1998).
Progesterone receptors have a close relationship with OR and
are known to be regulated by oestrogens (Rayter, 1991). However,
we found no significant difference between PR-negative and PR-
positive breast cancer tissues. In OR-positive breast cancer tissues,
there is no difference whether the tissue is also PR-positive or PR-
negative. Our findings that PR-transfected (ABC28) and untrans-
fected (MDA-MB-231) cells expressed similar levels of MT-1E
mRNA, and that progesterone treatment of ABC28 did not down-
regulate MT-1E mRNA expression suggest that the role of MT-1E
in OR-negative breast cancers is not mediated via the PR pathway.
In conclusion, we have demonstrated a higher MT-1E mRNA
expression in OR-negative than in OR-positive invasive ductal
breast cancer tissues which is independent of the PR status.
Whether MT-1E expression influences the poor prognosis associ-
ated with OR-negative breast tumours remains to be determined. It
is therefore worthwhile to extend studies on the role of MT-1E in
breast cancers by adopting molecular approaches.
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Figure 4 Agarose gel electrophoresis showing restriction enzyme cleavage
of MT-1E RT-PCR products. DNA marker (lanes 1 and 5); bgl-I digested
product (lane 2), showing expected 164 bp and 120 bp fragments;
undigested 284 bp product (lane 3); Ear-I digested product (lane 4), showing
137 bp and 108 bp fragments (39 bp fragment not shown).
Table 1 Mean values of MT-1E mRNA expression (relative to housekeeping
gene G3PDH) in human invasive ductal breast cancer tissues with OR and
PR status
OR+ (n = 35) OR– (n = 16) Total (n = 51)
PR+ (n = 17) 0.46±0.053 (17) (0) 0.46±0.053 (17)
PR– (n = 34) 0.44±0.053 (18) 0.68±0.10 (16) 0.54±0.058 (34)
Total (n = 51) 0.45±0.040 (35) 0.68±0.10 (16) 0.52±0.040 (51)
Results are expressed as mean ± sem. Brackets indicate number of casesREFERENCES
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